CKAP5: A Potential Drug Target for Various Diseases (G9793)

Target Name: CKAP5

NCBI ID: G9793

CKAP5: A Potential Drug Target for Various Diseases

CKAP5 (CHTOG) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of thecalbindin family of proteins, which are involved in the regulation of bone and muscle mass, as well as immune responses.

Recent studies have identified CKAP5 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern make it an attractive target for small molecule inhibitors.

One of the key reasons for the interest in CKAP5 is its role in the regulation of bone and muscle mass. Calbindin is a protein that is involved in the regulation of bone density and bone structure. It is expressed in high levels in regions of the body where bone is actively growing or changing, such as the jaw, spine, and legs.

CKAP5 is also involved in the regulation of muscle mass and structure. It is expressed in muscle fibers and is involved in the regulation of muscle contraction and relaxation. Its role in muscle mass regulation has been suggested as a potential target for drugs that aim to treat muscle-related diseases, such as muscular dystrophy.

In addition to its role in bone and muscle mass regulation, CKAP5 is also involved in the regulation of immune responses. It is a known regulator of T cell development and function, and has been shown to play a role in the regulation of inflammation.

Its unique expression pattern and structure make CKAP5 an attractive target for small molecule inhibitors. Studies have shown that inhibitors of CKAP5 have the potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, CKAP5 has been shown to be involved in the regulation of cell proliferation and survival. Its expression has been shown to be associated with the development and progression of various types of cancer, including breast, ovarian, and prostate cancer.

In neurodegenerative diseases, CKAP5 has been shown to be involved in the regulation of neurotransmitter signaling and the maintenance of neural stem cells. Its expression has been shown to be associated with the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In autoimmune disorders, CKAP5 has been shown to be involved in the regulation of immune responses and the regulation of inflammation. Its expression has been shown to be associated with the development and progression of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

In conclusion, CKAP5 is a protein that is involved in various physiological processes in the body, including bone and muscle mass regulation, immune responses, and neurotransmission. Its unique structure and expression pattern make it an attractive target for small molecule inhibitors. Further studies are needed to fully understand the role of CKAP5 in various diseases and to develop effective treatments.

Protein Name: Cytoskeleton Associated Protein 5

Functions: Binds to the plus end of microtubules and regulates microtubule dynamics and microtubule organization. Acts as processive microtubule polymerase. Promotes cytoplasmic microtubule nucleation and elongation. Plays a major role in organizing spindle poles. In spindle formation protects kinetochore microtubules from depolymerization by KIF2C and has an essential role in centrosomal microtubule assembly independently of KIF2C activity. Contributes to centrosome integrity. Acts as component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter-microtubule bridge. The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fiber tension (PubMed:23532825). Enhances the strength of NDC80 complex-mediated kinetochore-tip microtubule attachments (PubMed:27156448)

More Common Targets